Dr. Eric Kelsic is the CEO and co-founder of Dyno Therapeutics, a company pioneering the use of artificial intelligence (AI) to engineer novel adeno-associated virus (AAV) vectors for gene therapy. Before establishing Dyno, Dr. Kelsic led a team in Dr. George Church's lab at the Wyss Institute of Harvard Medical School, where he developed the technology that underpins Dyno's AI-powered capsid engineering platform. During this time, he measured the first comprehensive fitness landscape of the AAV capsid protein and co-discovered the AAV MAAP gene. 

Dr. Kelsic earned his Ph.D. in Systems Biology from Harvard University and holds a B.S. in Physics from the California Institute of Technology. Under his leadership, Dyno Therapeutics has secured significant venture capital financing, including a $109 million Series A funding round in 2021.